Centene (Centene) Risk Assessment

View and export this data going back to 2001. Start your Free Trial

What is Centene Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Centene is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of Centene's Risk Assessment

For the Healthcare Plans subindustry, Centene's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Centene's Risk Assessment Distribution in the Healthcare Plans Industry

For the Healthcare Plans industry and Healthcare sector, Centene's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Centene's Risk Assessment falls into.

Centene (NYSE:CNC) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Centene Risk Assessment Related Terms

Thank you for viewing the detailed overview of Centene's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Centene (Centene) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Plans » Centene Corp (NYSE:CNC) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

CNC:Mexico 1CNC:Italy QEN:Germany QEN:Germany C1NC34:Brazil

Address

7700 Forsyth Boulevard, Centene Plaza, St. Louis, MO, USA, 63105

Website

https://www.centene.com

Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of June 2023, mostly in Medicaid (67% of membership), the individual exchanges (14%), and Medicare Advantage (6%) plans. The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program.

Executives

Lori Jean Robinson	director	5875 LANDERBROOK DRIVE, SUITE 220, CLEVELAND OH 44124
Andrew Lynn Asher	officer: EVP, CFO	8735 HENDERSON ROAD, TAMPA FL 33634
James E Murray	officer: EVP, Chief Transform. Officer	500 WEST MAIN STREET, LOUISVILLE KY 40202
Samuels Theodore R. Ii	director	1990 E. GRAND AVE., EL SEGUNDO CA 90245
Monte E Ford	director	C/O AKAMAI TECHNOLOGIES, INC., 8 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Kenneth J Fasola	officer: EVP, Health Care Enterprises	500 WEST MAIN STREET, LOUISVILLE KY 40202
Shannon Bagley	officer: EVP, Chief Admin. Officer	7700 FORSYTH BOULEVARD, CLAYTON MO 63105
Richard A Gephardt	director	822 CAPITOL SQUARE PLACE, SW, WASHINGTON DC 20024
Christopher J Coughlin	director
H James Dallas	director	127 PUBLIC SQUARE, CLEVELAND OH 44114
Mark J Brooks	officer: SVP, Chief Information Officer	7700 FORSYTH BOULEVARD, ST. LOUIS MO 63105
David P Thomas	officer: EVP, MARKETS	7700 FORSYTH BOULEVARD, ST. LOUIS MO 63105
Leslie V Norwalk	director	C/O 3661 VALLEY CENTRE DRIVE SUITE 200, SAN DIEGO CA 92130
Wayne S Deveydt	director	120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Toney Colin A	officer: EVP, Mergers & Acquisitions	7700 FORSYTH BOULEVARD, ST. LOUIS MO 63105